RxDoctor Payments Data

Yvonne Davis, MD

Internal Medicine · Mount Pleasant, SCNPI 1639107162

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $500 of the $582 with a category attached, or 86.0%. Novartis accounts for 86.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $500 and has fallen 91.6% since, to $42 in 2023.

$582in general payments, 2019–2025

Across 4 payments — averaging $145.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$500
  • Acadia Pharmaceuticals Inc$40
  • Mylan Specialty L.p.$26
  • Neurocrine Biosciences, Inc.$16
$2,426,597in research payments, 2019–2025

Across 150 payments — averaging $16,177 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$1.1M
  • Sanofi Pasteur Inc.$980K
  • GSK$200K
  • Ferring International Pharmascience Center US$63K
  • Eli Lilly$30K
  • Ferring Pharmaceuticals AS$25K
  • plus $8K from 1 others

What the payments were for

  • Consulting fees$50086%
  • Food & beverage$8214%

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$582 in reported general payments places this provider in the 60th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$130,496
Medicare patients
342
Services billed
877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban867$158,173
JardianceEmpagliflozin170$28,502
MyrbetriqMirabegron226$26,728
TrulicityDulaglutide26$26,073
EntrestoSacubitril/Valsartan82$19,610
RytaryCarbidopa/Levodopa81$19,141
LinzessLinaclotide31$18,250
JanuviaSitagliptin Phosphate99$17,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,245
XareltoRivaroxaban103$17,008
FarxigaDapagliflozin Propanediol77$16,312
CreonLipase/Protease/Amylase35$12,295
Atorvastatin Calcium1,790$9,941
Spiriva RespimatTiotropium Bromide17$9,657
Pantoprazole Sodium762$9,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$500$19,61082 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Mount Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →